Significant Ownership of PharmaCyte Biotech, Inc.
- Signature - Title
- /s/ Joshua N. Silverman - Joshua N. Silverman, Chief Executive Officer and President
- Location
- Las Vegas, NV
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by PharmaCyte Biotech, Inc..
Follow Filing Activity
Follow PharmaCyte Biotech, Inc. and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of PharmaCyte Biotech, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QCLS | Q/C TECHNOLOGIES, INC. | Common Stock, par value $0.001 per share | 74% | $28,646,744 | 8,475,368 | PharmaCyte Biotech, Inc. | 14 Nov 2025 | ||
| FEMY | FEMASYS INC | Common Stock, par value $0.0001 per share | 7.9% | $2,762,382 | 4,932,825 | PharmaCyte Biotech, Inc. | 17 Mar 2026 |
Schedules 13D/G Reported by PharmaCyte Biotech, Inc.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.